Reoperative surgery was used as a treatment for patients with recurrent obstructing
cancer. In this group of patients intraperitoneal
chemotherapy was used in an attempt to prolong the beneficial effects of treatment. This aggressive approach may be recommended irrespective of patient performance status if the patient is not terminally ill. This treatment was associated with a high rate of postoperative complications (55%) but low mortality (7%). To avoid or reduce the incidence of postoperative complications, this treatment should be performed only by an experienced surgical oncologist. Long-term benefits of this treatment were related to
biologic factors reflected by
cancer origin in the appendix, low-grade
tumor histopathology, and a free interval of > 2 years. Treatment-related factors were completeness of cytoreduction and administration of intraperitoneal
chemotherapy. The best outcome was achieved with
pseudomyxoma peritonei of appendiceal origin with a time interval between surgeries of 2 or more years, a complete cytoreduction, and treatment with intraperitoneal
chemotherapy. This treatment modality can be recommended for palliation of patients with recurrent obstruction due to other gastrointestinal and ovarian
malignancies, although, long-term results may not be so encouraging as with appendix
tumors. In the group of
colorectal cancer patients treated by aggressive reoperative surgery and intraperitoneal
chemotherapy, 35.3 percent survived 1 year, which differs significantly from the 4-5 month survival
after treatment by the standard approach.